Roche announced in Shanghai on November 8, 2013 that a Phase III study specifically evaluating the efficacy of Avastin? (bevacizumab) in Chinese patients with advanced non-small cell lung cancer (NSCLC) met its primary endpoint in a Phase III study. The study demonstrated a progression-free survival (PFS) benefit for Chinese patients consistent with the results of the previous pivotal study E4599, which showed that patients receiving Avastin? based first-line therapy compared to chemotherapy alone. BEYOND is the first study to specifically target Avastin? in a Chinese population of patients with non-small cell lung cancer. Compared to patients receiving chemotherapy alone, patients receiving Avastin? in combination with paclitaxel and carboplatin in first-line treatment prolonged median disease-free survival by 2.7 months (9.2 months versus 6.5 months (HR=0.40, 95% CI 0.29 – 0.54; P=0.0001)). The results of the study showed that patients who received Avastin? combination therapy had a 60% reduced risk of disease progression compared to patients receiving chemotherapy alone, a benefit result consistent with the results of the E4599 study. ”Several global phase III clinical trials have demonstrated that Avastin? provides a significant benefit for patients with non-small cell lung cancer. The BEYOND study is the first to confirm the efficacy of Avastin? This positive finding is critical for patients and will be the basis for consideration by the Chinese Food and Drug Administration for approval of Avastin? related indications.” In addition, the BEYOND study did not identify any new drug safety issues and the associated adverse events were consistent with other previous Anvitin? trial results were consistent. Meanwhile, overall survival data are currently immature.